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Respiratory morbidity with recurrent respiratory symptoms, chronic inhaled 
medication use and frequent hospital admissions in the first two years of life is a 
common problem in very preterm and very low birth weight infants. We conducted a 
retrospective cohort study aiming to describe the respiratory morbidity at two years of 
corrected age of very preterm and very low birth weight infants and to identify 
potential risk factors for its development in a Portuguese-based population born in 
the modern neonatal care era. A total 59 children were studied. Thirteen (22.0%) had 
recurrent respiratory symptoms and 20.3% were using chronic respiratory 
medication. Health care utilization for respiratory causes was frequent (57.6%), 
particularly emergency department attendance (50.8%). Twenty-seven (45.8%) had 
additional outpatient visits for respiratory causes and hospital admission was 
necessary for 8 (13.6%) patients. Factors associated with increased recurrent 
respiratory symptoms included maternal hypertensive disorders during pregnancy, 
umbilical artery flow disturbances, being small for gestational age, bronchopulmonary 
dysplasia, retinopathy of prematurity, intraventricular hemorrhage and a weight 
percentile below 3 at 6, 12 and 24 months of corrected age. Premature rupture of 
membranes was negatively associated with respiratory morbidity. We conclude that 
respiratory morbidity is a common problem in our population and a frequent cause of 
health care utilization. If confirmed in larger studies, the risk factors found in our 
study, particularly those related to growth and weight gain during infancy, could 
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Preterm birth has increased over the last 20 years and survival rates have 
improved.1-7 Chronic respiratory problems remain a common complication of 
prematurity, and very preterm2,3,6,7 and very low birth weight (VLBW)6,8,9 infants are 
especially vulnerable.  
These children often experience recurrent respiratory symptoms, with wheezing 
being the most frequently described outcome.6,8-11 Recurrent cough is also common, 
as is the need for bronchodilators and inhaled corticosteroids.2 6,8,10,11 Rates of 
hospitalization are considerably higher in this population, with respiratory illnesses 
being the most common cause of admission.1-4,6-8,12-15 
Several perinatal2,3,10,13,16-18, neonatal2,4,7,9,11,13,15,19-21 and familial factors10,19,21-23, as 
well as early life exposures2,6,9,10,13,21,22 have also been associated with increased 
respiratory morbidity in the first years of life. 
Hospitalization rates usually decline after the second year of life and by school age 
symptoms typically become mild.1-3,6,7 However, in some individuals recurrent 
wheezing and pulmonary function impairment may persist throughout childhood and 
early adulthood.2,6,24-27   
The aim of this study is to describe respiratory morbidity at 2 years of corrected age 
for very preterm and VLBW infants and to identify potential risk factors for its 





Patients and Methods 
All children born at Centro Hospitalar de São João between January 1, 2009 and 
December 31, 2011 with less than 32 weeks of gestational age or less than 1500 g at 
birth and treated at the local neonatal intensive care unit (NICU) were included. 
Exclusion criteria were major malformations, chromosomal disorders, congenital 
TORCH infection, death during NICU stay and transfer to another hospital before 
completing 7 days at the local NICU.  
All information was collected retrospectively. Patients’ clinical files were consulted 
and data about demographics, perinatal and neonatal characteristics was recorded 
(Appendix I).  
Gestational age was defined by menstrual age (women with regular menstrual 
cycles), ultrasound examination (in the absence of a menstrual date or when a 
difference of two or more weeks existed between menstrual age and that derived 
sonographically), or the New Ballard Score (in the absence of obstetrical 
indexes).28,29 Small for gestational age (SGA) was defined as a birth weight below 
the 10th centile of Fenton’s fetal growth charts.30 
Histological chorioamnionitis was classified according to Blanc31 (stage I: 
intervilositis; stage II: chorionitis; stage III: chorioamnionitis; funisitis: 
polymorphonuclear leukocytes in the Wharton´s jelly or umbilical vessel walls; 
vasculitis: polymorphonuclear leukocytes in chorionic or umbilical blood vessel walls). 
Diagnosis of respiratory distress syndrome (RDS) was made using the Vermont 
Oxford Network criteria: (1) PaO2 < 50 mmHg in room air, central cyanosis in room 
air, a requirement for supplemental oxygen to maintain PaO2 > 50 mmHg or a 
requirement for supplemental oxygen to maintain a pulse oximeter saturation over 
85% within the first 24 h of life and (2) a chest radiograph consistent with RDS 
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(reticulogranular appearance to lung fields with or without low lung volumes and air 
bronchograms) within the first 24 h of life. RDS was classified as light, moderate or 
severe according to X-ray appearance ranging from a light reticulogranular pattern 
with air bronchograms to white lungs, an adaptation from the classification by 
Couchard et al.32 
Bronchopulmonary dysplasia (BPD) was defined according to the National Institute of 
Child Health and Human Development consensus criteria.33,34 Patent ductus 
arteriosus (PDA) was considered when a hemodynamically significant defect was 
diagnosed on echocardiography. Diagnosis and staging of necrotizing enterocolitis 
(NEC) was made using the modified Bell criteria.35 Retinopathy of prematurity (ROP) 
was staged according to the International Classification.36 Proven neonatal sepsis 
was defined as any systemic bacterial or fungal infection documented by a positive 
blood culture. 
Intraventricular hemorrhage (IVH) was classified according to Papile et al37 (grade I: 
germinal matrix hemorrhage; grade II: IVH without ventricular dilation; grade III: IVH 
with ventricular dilation; grade IV: germinal matrix hemorrhage or IVH with 
parenchymal involvement). 
Afterwards, information about respiratory morbidity, care and evolution during the first 
two years of life (Appendix II) was collected in a single interview with the patients’ 
parents conducted at a routine hospital visit for the child or telephonically for those 
who had no scheduled visits or missed their appointments 
Weight percentiles at 6, 12 and 24 months of corrected age were defined according 
to the World Health Organization Child Growth Standards.38  




Written or oral consent was obtained after the parents were fully informed about the 
study’s design and purpose. 
This study was approved by the Centro Hospitalar de São João’s ethics committee. 
Statistical analysis was performed using SPSS 19 (IBM, New York, USA). 
Categorical variables were described using absolute and relative frequencies and 
continuous variables (with non-symetrical distribution) as median and range. We 
used chi-square test to explore associations for categorical variables and 
Mann-Whitney test for continuous variables. Results are presented as odds ratio 






A total 119 patients met the inclusion criteria. Thirteen were excluded for 
malformations, 5 for chromosomal disorders, 13 for death during NICU stay and 16 
for transfer to another hospital before completing 7 days at the local NICU. 
Additionally, 12 children were excluded for loss of follow-up and 1 for parents’ refusal 
to participate. A total 59 children were studied. 
The populations’ demographics, perinatal and neonatal data are summarized in 
Table 1. Table 2 describes the participants’ care and evolution after discharge, social 
and familiar characteristics. 
In the first two years of life, 13 (22.0%) had recurrent respiratory symptoms and 12 
(20.3%) were using chronic respiratory medication. Health care utilization for 
respiratory causes was frequent (57.6%), particularly emergency department 
attendance (50.8%). Hospital admission was necessary for 8 (13.6%) patients. 
Twenty-seven (45.8%) had additional outpatient visits for respiratory causes. 
Eighteen (30.5%) parents had to miss at least one day at work for their child’s 
respiratory problems (Table 3). 
Being SGA was significantly associated with the presence of recurrent respiratory 
symptoms (OR 3.84, 95% CI 1.02-14.37), as were maternal hypertensive disorders 
during pregnancy (OR 4.17, 95% CI 1.02-17.05) and umbilical artery flow 
disturbances (OR 10.67, 95% CI 2.61-43.64). Premature rupture of membranes 
(PROM) was negatively associated with the presence of respiratory symptoms in the 
first two years of life (Table 4).  
BPD (OR 9.78, 95% CI 1.55-61.73), ROP (stage ≥ II) (OR 5.00, 95% CI 1.03-24.30) 
and IVH (grade ≥ III) had significant positive associations with respiratory morbidity, 
as did a weight percentile below 3 at 6, 12 and 24 months of corrected age (Table 4). 
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We found no significant associations for gestational age, birth weight, SNAPPE-II 
and CRIB scores, maximal fraction of inspired O2 during NICU stay, duration of NICU 
stay, duration of breastfeeding, number of people in the household and age at 





The prevalence of respiratory symptoms and chronic respiratory medication use in 
our population is lower than that described in most studies.6,11,12,18,40,41 The great 
variability in inclusion and exclusion criteria, definition of outcomes and age at 
evaluation among studies makes it difficult to compare results. Still, the fact that our 
population is highly selected, excluding outborn patients with potentially more severe 
neonatal disease justifying their transfer to a tertiary center, could explain some of 
the differences observed. Also, the low prevalence of BPD in our population (10.2%), 
although comparable to a previous Portuguese study (12.9%)42, could contribute to 
the overall low respiratory morbidity. However, rates described for preterm children 
without BPD are still higher than those we found.11,41 Differences in prescription 
criteria could explain some variations in medication use as well.  
The rate of hospital admissions for respiratory causes was also lower than that found 
in previous studies, although similar rates have been described.2,11,40,41,43 Once 
again, differences in inclusion and exclusion criteria, age at evaluation and admission 
criteria make any conclusive comparisons difficult. 
We found a significant association between being SGA and recurrent respiratory 
symptoms. While some have found a significant association between intrauterine 
growth restriction (IUGR) and persistent wheezing, others failed to confirm it.19,44 Still, 
our results are supported by animal studies showing an association between IUGR 
and persisting alterations in lung structure and function and by findings of abnormal 
lung function in school aged children born SGA.45,46  
While no studies have described an association between umbilical artery flow 
disturbances and respiratory morbidity during infancy, we believe our results to be 
consistent with those by Hartung et al47 describing a positive association between 
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absent or reversed end-diastolic umbilical artery flow and BPD. Also, our findings of a 
positive association between hypertensive disorders of pregnancy and recurrent 
respiratory symptoms are in line with those by Rusconi et al.48  
It is possible that IUGR, hypertensive disorders of pregnancy and umbilical artery 
flow abnormalities represent to some extent a common pathway of placental 
insufficiency and altered angiogenesis, as proposed by others.49, 50 However, more 
studies are necessary to confirm this. 
We found a negative association between PROM and recurrent symptoms. Teune et 
al16 found the opposite and Williams et al51 described an increased incidence of 
hospital admissions for respiratory causes in these infants. However, PROM has 
been associated with a reduced risk of RDS. The proposed biological mechanism 
behind this association states PROM as an inflammation inducer that accelerates 
lung maturity.2, 52 Therefore, although lacking support from epidemiological studies, 
we believe our findings to be biologically plausible as infants with PROM may present 
with less RDS and need less aggressive respiratory interventions, and therefore 
develop less respiratory morbidity. 
Cesarean section has been associated with the development of asthma and 
recurrent wheezing.53,54 The lack of exposure to vaginal flora could alter immune 
system development in these children, with a subsequent increased risk for asthma 
and atopy.53,54 Because we studied a very young population, we didn’t include 
asthma diagnosis as a respiratory outcome; follow-up of this population is crucial to 
clarify whether those with recurrent respiratory symptoms during infancy are 
diagnosed with asthma in the future.54,55 
Our findings of a positive association between BPD and respiratory morbidity during 
infancy are in line with what has been described.4,7,11,19,21 
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ROP and IVH were also significantly associated with recurrent respiratory symptoms. 
We found no studies describing a relation between these disorders and respiratory 
morbidity in the first years of life. However, they appear to share common risk factors  
and an association between ROP and BPD has been described.42,56-58 Also, because 
we didn’t exclude children with neurological disorders, it is possible that infants with 
ROP and particularly IVH represent those with the worst neurological outcome, which 
may account for their increased respiratory morbidity.59-61 
Having a weight percentile below 3 at 6, 12 or 24 months was significantly associated 
with respiratory morbidity. Most studies have described the negative effects of rapid 
weight gain or being overweight on pulmonary function  and the development of 
asthma and recurrent wheezing.62-64 However, these findings are not universal65 and 
a study by Zhang et al66 found that being overweight during the first two years of life 
was associated with a decreased risk of asthma and better lung function. Proposed 
explanations emphasized the influence of a well-nourished state in promoting 
maximal postnatal lung development at an age when great alveolar development and 
multiplication occurs.66 Because we chose to focus on the effects of poor weight 
evolution and underweight persistence, the extent to which our results may be 
compared to previous reports is limited.  
The small number of participants is one of our study’s limitations and may justify the 
lack of significant associations between respiratory morbidity and several of the 
factors we tested for. We chose to define outcomes as reported by parents, a method 
frequently used in other studies4; however, it creates the potential for information 
bias. Also, the study’s retrospective design creates the possibility of recall bias.  
Future studies with larger samples are needed to clarify the significance of our 
findings. The creation of predictive models for respiratory morbidity in the first years 
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but also later in life would be an interesting goal, allowing a more accurate 
identification of children who might benefit from closer follow-up and specific 
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Tables and Figures 
 
Table 1– Demographics, perinatal and neonatal characteristics of the study 
population 
 Total (n=59) 
Demographics   
Female, n (%) 36   (61.0) 
Gestational age (weeks), median (range) 30   (25-37) 
Birth weight (g), median (range) 1195  (520 – 2435) 
Small for gestational age (SGA), n (%) 26 (44.1) 
Assymetrical SGA, n (%) 7 (11.9) 
Gestation   
Multiple gestation, n (%) 21  (35.6) 
Prenatal corticosteroids, n (%) 54 (91.5) 
Incomplete cycle, n (%) 9 (15.3) 
Complete cycle, n (%) 45 (76.3) 
Smoking during pregnancy, n (%) 9  (15.3) 
Gestational diabetes, n (%) 5 (8.5) 
Chronic maternal hypertension, n (%) 3 (5.1) 
Hypertensive disorders of pregnancy, n (%) 11 (18.6) 
Pre-eclampsia, n (%) 9 (15.3) 
Eclampsia, n (%) 1 (1.7) 
HELLP syndrome, n (%) 2 (3.4) 
Histological chorioamnionitis, n (%) 19 (32.2) 
Funisitis and/or chorionic vasculitis, n (%) 10 (16.9) 
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Clinical chorioamnionitis, n (%) 2 (3.4) 
Placental abruption, n (%) 3 (5.1) 
Umbilical artery flow disturbances*, n (%) 14 (23.7) 
Delivery   
Caesarian section, n (%) 49 (83.1) 
Premature rupture of membranes, n (%) 10 (16.9) 
Hours of membrane rupture, median (range) 62 (3-1992) 
Intrapartum antibiotics for premature rupture of 
membranes, n (%) 
6 (10.2) 
APGAR (1st minute)    
0-3, n (%) 6 (10.2) 
4-6, n (%) 15 (25.4) 
7-10, n (%) 38 (64.4) 
APGAR (5th minute)**     
0-3, n (%) 1 (1.7) 
4-6, n (%) 6 (10.3) 
7-10, n (%) 51 (87.9) 
Need for resuscitation, n (%) 30 (50.8) 
Early CPAP, n (%) 27 (45.8) 
Neonatal period (NICU stay)  
SNAPPE-II score***  
0-9, n (%) 32 (54.2) 
10-19, n (%) 6 (10.2) 
20-29, n (%) 8 (13.6) 
30-39, n (%) 3 (5.1) 
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40-49, n (%) 2 (3.4) 
50-59, n (%) 1 (1.7) 
60-69, n (%) 1 (1.7) 
70-79, n (%) 0 (0.0) 
≥ 80, n (%) 0 (0.0) 
CRIB score***   
0-5, n (%) 47 (79.7) 
6-10, n (%) 6 (10.2) 
11-15, n (%) 0 (0.0) 
≥ 16, n (%) 0 (0.0) 
RDS, n (%) 29 (49.2) 
Mild, n (%) 13 (22.0) 
Moderate, n (%) 11 (18.6) 
Severe, n (%) 5 (8.5) 
Surfactant administration, n (%) 29 (49.2) 
Conventional mechanical ventilation, n (%) 27 (45.8) 
Invasive ventilation only, n (%) 1 (1.7) 




nCPAP only, n (%) 24 (40.7) 
Days of conventional mechanical ventilation, median (range) 7 (1-59) 
Days of nCPAP, median (range) 27 (2-62) 
Supplemental oxygen, n (%) 29 (49.2) 
Maximal fraction of inspired O2, median (range) 0.21 (0.21-1.00) 
Days of supplemental oxygen, median (range) 7 (1-121) 
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Supplemental oxygen on discharge, n (%) 1 (1.7) 
Bronchopulmonary dysplasia, n (%) 6 (10.2) 
Mild, n (%) 2 (3.4) 
Moderate, n (%) 1 (1.7) 
Severe, n (%) 3 (5.1) 
Patent ductus arteriosus, n (%) 14 (23.7) 
Necrotizing enterocolitis (≥2A), n (%) 3 (5.1) 
Retinopathy of prematurity (≥II), n (%) 8 (13.6) 
Intraventricular hemorrhage (≥ III), n (%) 3 (3.4) 
Hidrocephalus, n (%) 2 (3.4) 
Periventricular cystic leukomalacia, n (%) 6 (15.3) 
Sepsis, n (%) 23 (39.0) 
Days at the UCIN, median (range) 43 (7-154) 
Weight on discharge (g), median (range) 1920 (848-2800) 
Weight percentile on discharge   
< 3, n (%) 43 (72.9) 
≥ 3, n (%) 16 (27.1) 
Season of discharge   
Spring, n (%) 22 (37.3) 
Summer, n (%) 14 (23.7) 
Autumn, n (%) 8 (13.6) 
Winter, n (%) 15 (25.4) 
 
* Includes umbilical artery flow absence or inversion ;**n=58; ***n=53. 
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Table 2 – Care and evolution after discharge from NICU 
 Total (n=59) 
Breastfeeding, n (%) 34 (57.6) 
Duration of breastfeeding (months), median (range) 3 (1-27) 
Isolation during first winter season, n (%) 17 (28.8) 
Other preventive measures, n (%) 35 (59.3) 
Antipneumococcal vaccine, n (%) 57 (96.6) 
Palivizumab, n (%) 47 (79.7) 
Influenza vaccine, n (%) 20 (33.9) 
Weight percentile at 6 months of corrected age, n (%)  
< 3, n (%) 12 (20.7) 
≥ 3, n (%) 46 (79.3) 
Weight percentile at 12 months of corrected age, n (%)  
< 3, n (%) 9 (16.1) 
≥ 3, n (%) 47 (83.9) 
Weight percentile at 24 months of corrected age, n (%)  
< 3, n (%) 5 (8.8) 
≥ 3, n (%) 52 (91.2) 
Social and familiar characteristics   
Socioeconomical status (Graffar classification)   
Class I, n (%) 17 (28.8) 
Class II, n (%) 20 (33.9) 
Class III, n (%) 18 (30.5) 
Class IV, n (%) 4 (6.8) 
Class V, n (%) 0 (0.0) 
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Number of people in the household, median (range) 4 (2-7) 
Preschool aged siblings, n (%) 24 (40.7) 
Stayed at home during the first two years of life, n (%) 44 (74.6) 
Day care attendance, n (%) 15 (25.4) 
Age at beginning of day care attendance, median 
(range)    
9 (0-20) 
Any smokers in the household, n (%) 27 (45.8) 
Fireplace in the household, n (%) 26 (44.1) 
Family history of asthma, n (%) 24 (40.7) 
Maternal, n (%) 13 (22.0) 
Family history of atopy, n (%) 22 (37.3) 
Maternal, n (%) 12 (20.3) 
 








Recurrent respiratory symptoms, n (%) 13 (22.0) 
Recurrent cough, n (%) 4 (6.8) 
Recurrent wheeze, n (%) 3 (5.1) 
Recurrent respiratory symptoms on exertion, n (%) 10 (16.9) 
Waking with cough, n (%) 4 (6.8) 
Waking with wheeze, n (%) 3 (5.1) 
Waking with dyspnea, n (%) 4 (6.8) 
Respiratory symptoms with respiratory illness only, n (%) 30 (50.8) 
Cough, n (%) 33 (55.9) 
Wheeze, n (%) 28 (47.5) 
Need for respiratory medication 
Chronic respiratory medication*, n (%) 12 (20.3) 
Long acting β agonists, n (%) 0 (0.0) 
Daily inhaled corticosteroids, n (%) 5 (8.5) 
Daily short acting β agonists, n (%) 2 (3.4) 
Frequent inhaled antimuscarinics use, n (%) 2 (3.4) 
Daily leukotriene antagonists use, n (%) 2 (3.4) 
Frequent antihistamines use, n (%) 5 (8.5) 
Respiratory medication for respiratory illness only**, n (%) 25 (42.4) 
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Health care utilization 
Health care utilization for respiratory causes, n (%) 34 (57.6) 
Additional outpatient visits for respiratory causes, n (%) 27 (45.8) 
Emergency department attendance for respiratory causes, n (%) 30 (50.8) 
Emergency department attendance for bronchiolitis, n (%) 16 (27.1) 
Emergency department attendance for pneumonia, n (%) 2 (3.4) 
Emergency department attendance for other respiratory 
causes, n (%) 
17 (28.8) 
Hospital admission for respiratory causes, n (%) 8 (13.6) 
Hospital admission for bronchiolitis, n (%) 7 (11.9) 
Hospital admission for pneumonia, n (%) 1 (1.7) 
Hospital admission for other respiratory causes, n (%) 3 (5.1) 
Impact on parents’ life   
Any missed days at work, n (%) 18 (30.5) 
Number of days missed at work by parents, median (range) 7 (2-10) 
 
*Includes inhaled long and short acting β agonists, inhaled antimuscarinics, inhaled 
corticosteroids, oral leukotriene antagonists and oral antihistamines; **Includes 
inhaled long and short acting β agonists, inhaled antimuscarinics, inhaled 












Overall 13 (22.0)   
Sex   
0.49 
      Female 9 (25.0) 1.00 (ref) 
      Male  4 (17.4) 0.63 (0.17-2.36) 
Small for gestational age (SGA)   
0.04 
      No  4 (12.1) 1.00 (ref) 
      Yes  9 (34.6) 3.84 (1.02-14.37) 
Assymetrical SGA   
0.58 
      No 12 (23.1) 1.00 (ref) 
      Yes   1 (14.3) 0.56 (0.06-5.08) 
Prenatal corticosteroids   
0.21 
      No 0 (0.0) 1.00 (ref) 
      1 dose   3 (33.3) n.a. 
      2 doses 10 (22.2) n.a. 
Smoking during pregnancy   
0.36 
      No 12 (24.0) 1.00 (ref) 
      Yes   1 (11.1) 0.40 (0.05-3.49) 
Gestational diabetes   
0.11 
      No 13 (24.1) 1.00 (ref) 
      Yes 0 (0.0) n.a. 
   0.06 
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Chronic maternal hypertension 
      No 11 (19.6) 1.00 (ref) 
      Yes   2 (66.7) 8.18 (0.68-98.62) 




      No   8 (16.7) 1.00 (ref) 
      Yes   5 (45.5) 4.17 (1.02-17.05) 
Placental disorders*   
0.79 
      No   9 (23.1) 1.00 (ref) 
      Yes   4 (20.0) 0.83 (0.22-3.14) 
Umbilical artery flow disturbances**   
0.001 
      No    5 (11.1) 1.00 (ref) 
      Yes    8 (57.1) 
10.67 
(2.61-43.64) 
Caesarian section   
0.02 
      No  0 (0.0) 1.00 (ref) 
      Yes  13 (26.5) n.a. 
Premature rupture of membranes   
0.02 
      No   13 (26.5) 1.00 (ref) 
      Yes  0 (0.0) n.a. 
APGAR (5th minute)   
0.68 
       0-6    2 (28.6) 1.00 (ref) 







Need for resuscitation 
      No    5 (17.2) 1.00 (ref) 
      Yes    8 (26.7) 1.75 (0.50-6.14) 
Early CPAP   
0.06 
      No   10 (31.3) 1.00 (ref) 
      Yes    3 (11.1) 0.28 (0.70-1.13) 
RDS   
0.38 
      No   8 (26.7) 1.00 (ref) 
      Yes   5 (17.2) 0.57 (0.16-2.02) 
Surfactant administration   
0.81 
      No   7 (23.3) 1.00 (ref) 





      No   7 (21.9) 1.00 (ref) 
0.97       Yes   6 (22.2) 1.02 (0.30-3.51) 
nCPAP only   
0.13 
      No   10 (28.6) 1.00 (ref) 
      Yes    3 (12.5) 0.36 (0.09-1.47) 
Supplemental oxygen   
0.70 
      No   6 (20.0) 1.00 (ref) 
      Yes   7 (24.1) 1.27 (0.37-4.37) 
Bronchopulmonary dysplasia   
0.01 
      No   9 (17.0) 1.00 (ref) 
      Yes   4 (66.7) 9.78 (1.55-61.73) 
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Patent ductus arteriosus   
0.95 
      No   10 (22.2) 1.00 (ref) 
      Yes    3 (21.4) 0.96 (0.22-4.10) 
Necrotizing enterocolitis (≥2A)   
0.64 
      No   12 (21.4) 1.00 (ref) 
      Yes    1 (33.3) 1.83 (0.15-21.98) 
Retinopathy of prematurity (≥II)   
0.05 
      No    8 (16.7) 1.00 (ref) 
      Yes    4 (50.0) 5.00 (1.03-24.30) 
Intraventricular hemorrhage (≥ III)   
0.01 
      No   11 (19.3) 1.00 (ref) 
      Yes       2 (100.0) n.a. 
Hidrocephalus   
0.38 
      No   12 (21.1) 1.00 (ref) 
      Yes    1 (50.0) 3.75 (0.22-64.44) 
Periventricular cystic leukomalacia   
0.36 
      No 12 (24.0) 1.00 (ref) 
      Yes   1 (11.1) 0.40 (0.05-3.49) 
Sepsis   
0.22 
      No   6 (16.7) 1.00 (ref) 
      Yes  7 (30.4) 2.19 (0.63-7.62) 
Weight percentile on discharge   
0.71 
< 3 10 (23.3) 1.00 (ref) 
≥ 3 3 (18.8) 0.76 (0.18-3.22) 
   0.90 
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Season of discharge 
Spring 4 (18.2) 1.00 (ref) 
Summer 4 (28.6) 1.80 (0.37-8.80) 
Autumn 2 (25.0) 1.50 (0.22-10.36) 
Winter 3 (20.0) 1.13 (0.21-5.95) 
Breastfeeding   
0.35 
      No    7 (28.0) 1.00 (ref) 
      Yes    6 (17.6) 0.55 (0.16-1.91) 
Isolation during first winter season   
0.60 
      No    10 (23.8) 1.00 (ref) 
      Yes     3 (17.6) 0.67 (0.16-2.88) 
Antipneumococcal vaccine   
0.34 
      No***     2 (40.0) 1.00 (ref) 
      Yes   11 (20.4) 0.38 (0.06-2.59) 
Palivizumab   
0.31 
      No    4 (33.3) 1.00 (ref) 
      Yes    9 (19.1) 0.47 (0.12-1.93) 
Influenza vaccine   
0.31 
      No    8 (18.6) 1.00 (ref) 
      Yes    5 (31.3) 1.99 (0.54-7.35) 




< 3 7 (58.3) 1.00 (ref) 
≥ 3 6 (13.0) 0.11 (0.03-0.45) 
   0.001 
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Weight percentile at 12 months of 
corrected age 
< 3 6 (66.7) 1.00 (ref) 
≥ 3 6 (12.8) 0.07 (0.01-0.37) 




< 3 4 (80.0) 1.00 (ref) 
≥ 3 9 (17.3) 0.05 (0.01-0.53) 




Class I 4 (23.5) 1.00 (ref) 
Class II 2 (10.0) 0.36 (0.06-2.28) 
Class III 6 (33.3) 1.63 (0.37-7.20) 
Class IV 1 (25.0) 1.08 (0.09-13.54) 
Preschool aged siblings   
0.13 
      No 10 (28.6) 1.00 (ref) 
      Yes   3 (12.5) 0.36 (0.09-1.47) 
Day care attendance   
0.33 
      No 11 (25.0) 1.00 (ref) 
      Yes  2 (13.3) 0.46 (0.09-2.37) 
Any smokers in the household   
0.97 
      No  7 (21.9) 1.00 (ref) 







Fireplace in the household 
      No  9 (27.3) 1.00 (ref) 
      Yes  4 (15.4) 0.49 (0.13-1.80) 
Family history of asthma   
0.85 
      No   8 (22.9) 1.00 (ref) 
      Yes  5 (20.8) 0.89 (0.25-3.14) 
Family history of atopy   
0.17 
      No  6 (16.2) 1.00 (ref) 
      Yes 7 (31.8) 2.41 (0.69-8.44) 
 
*Includes histological chorioamnionitis, funisitis and chorionic vasculitis;** Includes 
umbilical artery flow absence or inversion; *** Incomplete immunization (1 or 2 







APPENDIX I – Questionnaire about demographic, perinatal and neonatal data 
 
RESPIRATORY MORBIDITY IN VERY PRETERM AND VERY LOW BIRTH WEIGHT INFANTS – 





Birth date   ___ / ___ / _______ 
Sex  F(0)  M(1)  
Gestational age     _________ days 
Birth weight _________ g 
Small for gestational age (SGA) no (0)  yes (1)  




Multiple gestation  no (0)  yes (1)   
 
Prenatal corticosteroids  no (0)  incomplete cycle (one betamethasone administration)(1)   
Complete cycle (two betamethasone administrations) (2)  
 
Smoking during pregnancy no(0)  yes(1)  
 
Gestational diabetes  no(0)  yes(1)   
 
Chronic maternal hypertension  no(0)  yes(1)  
Pre-eclampsia    no(0)  yes(1)  
Eclampsia    no(0)  yes(1)  
HELLP syndrome    no(0)  yes(1)  
 
Placental histology: 
Histological chorioamnionitis no(0)  stage I (1)    stage II (2)    stage III (3)      
39 
 
Funisitis    no(0)   yes(1)  
Chorionic vasculitis  no(0)   yes(1)  
 
Clinical chorioamnionitis     no(0)  yes(1)   
Placental abruption     no(0)  yes(1)  




Type of delivery   eutocic (0)  cesarean section (1)  
 
Premature ruprture of membranes no(0)  yes(1)       
 
Intrapartum antibiotics no(0)  yes(1)       Justification:____________________________________
  
APGAR (1st and 5th minutes) ____  /  ____  /  ____ 
 




SNAPPE-II _________  CRIB _____________ 
 
Respiratory distress syndrome  no (0)      light (1)      moderate (2)      severe (3)    
 
Surfactant administration  no (0)  yes(1)   
 
Conventional mechanical ventilation (>12h) no(0)   yes(1)   Duration: ______days 
nCPAP (>12h)     no(0)   yes(1)   Duration: ______days 
  
Higher FiO2 (>24h): _______   
Duration of oxygen supplementation: ______ days 
 
Bronchopulmonary dysplasia   no (0)      light(1)      moderate(2)      severe(3)   
 




Necrotizing enterocolitis (grade ≥ 2A Bell)  no(0)   yes(1)  
 
Retinopathy of prematurity (higher stage)  no(0)  stage I (1)  stage II (2)  stage III (3)  
      grau IV (4)  grau V (5)  
  
Intraventricularvhemorrhage  no (0)  stage I (1)    stage II (2)  stage III (3)    stage IV (4)  
Hidrocephalus (with ventriculoperitoneal derivation)  no(0)   yes(1)  
Periventricular leukomalacia     no(0)   yes(1)  
  
Sepsis    no(0)  yes(1)     
 
Days at NICU:  _______  
 
Weight on discharge:  _________ g;  
Weight percentile on discharge (Fenton curves):   <3 (0)   ≥ 3 (1)  
 




APPENDIX II – Questionnaire about social and familiar data and follow-up in the first 
two years of life 
 
RESPIRATORY MORBIDITY IN VERY PRETERM AND VERY LOW BIRTH WEIGHT INFANTS – 
THE FIRST TWO YEARS OF LIFE 
 
ID: ___________ 
Date at two years of corrected age: __________________________ 
 
FOLLOW-UP AFTER NICU DISCHARGE (FIRST TWO YEARS OF LIFE) 
 
1. CARE AND EVOLUTION 
Breastfeeding (≥ one month)   no(0)  yes(1)   Duration: _____months 
 
Isolation during first winter season   no(0)  yes(1)  
Other preventive measures after discharge (avoidance of crowded spaces, avoidance of tobacco smoke 
exposure, adequate hand hygiene)  no(0)  yes(1)  
 
Antipneumococcal vaccine  no(0)  complete (3 administrations) (1)   
incomplete (< 3 administrations) (2)  
Palivizumab  no(0)  yes(1)    
Influenza vaccine  no(0)  yes(1)     
 
Weight percentile at 6 months of corrected age (WHO curves):   <3 (0)   ≥ 3 (1)  
Weight percentile at 12 months of corrected age (WHO curves):   <3 (0)   ≥ 3 (1)  
Weight percentile at 24 months of corrected age (WHO curves):   <3 (0)   ≥ 3 (1)  
 
2. SOCIAL AND FAMILIAL FACTORS 
Number of people in the household (patient included): ______ 
Any preschool aged siblings  no(0)  yes(1)   
Attended daycare   no(0)  yes(1)   
Age at beginning of daycare attendance:___ months 
Any smokers in the household  no(0)  yes(1)   




Graffar’s classification (according to Amaro, (2001). A classificação das famílias segundo a Escala de Graffar. Lisboa: 
Fundação Nossa Senhora do Bom Sucesso):  Class I(1)   Class II (2)  Class III(3)   
 Class IV(4)  Class V(5)  
 
Family history of asthma  no(0)  yes(1)    
Maternal asthma  no(0)  yes(1)    
 
Family history of atopy  no(0)  yes(1)    
Maternal atopy   no(0)  yes(1)   
 
 




Frequent cough     no(0)  yes(1)   
Frequent wheeze   no(0)  yes(1)   
Cough, wheeze or dyspnea with exertion  no(0)  yes(1)   
Waking with cough    no(0)  yes(1)     
Waking with wheeze    no(0)  yes(1)   
Waking with dyspnea   no(0)  yes(1)    
 
Cough with respiratory illness only  no(0)  yes(1)   




Inhaled long acting β agonists no(0)      chronic use(1)      use for respiratory illness only (2)  
Inhaled corticosteroids  no(0)      chronic use(1)      use for respiratory illness only (2)  
Inhaled short acting β agonists no(0)      chronic use(1)      use for respiratory illness only (2)  
Inhaled antimuscarinics  no(0)      chronic use(1)      use for respiratory illness only (2)  
Oral antihistamines  no(0)      chronic use(1)      use for respiratory illness only (2)  
Leukotriene antagonists  no(0)  yes(1)  
 
 
3.3) HEALTH CARE UTILIZATION 





Additional outpatient visits for respiratory causes  no(0)  yes(1)   
 
EMERGENY DEPARTMENT (ED) 
Any ED attendance for respiratory causes   no(0)  yes(1)   
Any ED attendance for bronchiolitis  no(0)  yes(1)   
Any ED attendance for penumonia   no(0)  yes(1)  
Any ED attendance for other respiratory causes no(0)  yes(1)  
 
HOSPITAL ADMISSIONS 
Any hospital admission for respiratory causes   no(0)  yes(1)  
Any hospital admission for bronchiolitis   no(0)  yes(1)  
Any hospital admission for pneumonia   no(0)  yes(1)  
Any hospital admission for other respiratory causes  no(0)  yes(1)   
 
3.4) IMPACT ON PARENTS’ LIFE 
Any days missed at work for the child’s respiratory problems   no(0)  yes(1)   
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Instruções aos Autores
A Revista Portuguesa de Pneumologia considera para publicação 
trabalhos (artigos originais, de revisão, casos clínicos, 
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as autorizações necessárias para a publicação do material 
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conselho editorial da revista. 
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g) Quadros e Figuras.
Autoria — Como referido nos “Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals.”, a autoria 
requer uma contribuição substancial para o manuscrito. É pois 
necessário especificar na carta de apresentação o contributo 
de cada autor para o trabalho.
Exemplo: António Costa concebeu o estudo e supervisionou 
todos os aspectos da sua implementação. José Costa 
colaborou na concepção do estudo e efectuou a análise 
dos dados. Manuel Costa efectuou a recolha de dados e 
colaborou na sua análise. Todos os autores contribuíram 
para a interpretação dos resultados e revisão dos rascunhos 
do manuscrito. 
Apresentação dos trabalhos — Todo o manuscrito, incluindo 
referências, tabelas e legendas de figuras, deve ser redigido a 
dois espaços, com letra a 12 pontos, e justificado à esquerda. 
Devem ser numeradas todas as páginas, incluindo a página do 
título. Devem ser apresentadas margens com 2,5 cm em todo o 
manuscrito. Devem ser inseridas quebras de página entre cada 
secção. Nos manuscritos assinados por mais de 6 autores (3 
autores no caso das cartas ao editor), tem que ser explicitada 
a razão de uma autoria tão alargada. 
TIPOLOGIA DOS ARTIGOS 
Artigos de investigação original - O texto deve ser limitado a 
2000 palavras, excluindo referências e tabelas, e organizado 
em introdução, métodos, resultados e discussão, com um 
máximo de 4 tabelas e/ou figuras (total). Nos materiais e 
métodos deverá haver uma referência completa e adequada 
aos métodos estatísticos usados e os resultados deverão estar 
suficientemente explícitos. 
Artigos de revisão - A Revista Portuguesa de Pneumologia 
publica essencialmente artigos de revisão solicitados pelos 
editores. Contudo, também serão avaliados artigos de revisão 
submetidos sem solicitação prévia, preferencialmente revisões 
sistemáticas (meta-análise). O texto deve ser limitado a 
5000 palavras, excluindo referências e tabelas, e apresentar 
um máximo de 5 tabelas e/ou figuras (total). As revisões 
sistemáticas devem ser organizadas em introdução, métodos, 
resultados e discussão. 
Publicações breves 
Resultados preliminares ou novas descobertas podem ser 
objecto de publicações breves. O texto deve ser limitado a 
1000 palavras, excluindo referências e tabelas, e organizado 
em introdução, métodos, resultados e discussão, com um 
máximo de 2 tabelas e/ou figuras (total) e até 10 referências. 
As publicações breves devem apresentar resumos estruturados 
em português e em inglês, com um máximo de 250 palavras 
cada. 
Comentários
Comentários, ensaios, análises críticas ou declarações de 
posição sobre tópicos de interesse na área da saúde, 
designadamente políticas de saúde e educação médica. O 
texto deve ser limitado a 900 palavras, excluindo referências 
e tabelas, e incluir no máximo uma tabela ou figura. Os 
comentários não devem apresentar resumos. Na maior parte 
dos casos este tipo de artigo será solicitado pelos editores.
Artigos especiais 
Quando se justifique o corpo editorial convidará um ou 
vários autores para elaborarem um artigo cujo interesse 
formativo atinja as prioridades da revista e cujo tema não 
seja contemplado noutra tipologia (por exemplo formação 
pós-graduada).
Casos clínicos — O texto deve ser limitado a 1200 palavras, 
excluindo referências e tabelas, com um máximo de 2 tabelas 
e/ou figuras (total). Os casos clínicos devem apresentar 
resumos não estruturados em português e em inglês, com um 
máximo de 120 palavras cada.  
De acordo com o seu interesse e originalidade pode ser incluído 
no caso clínico um comentário/discussão de um dos editores 
ou revisor convidado (Caso clínico com discussão).
Cartas ao editor — Comentários sucintos a artigos publicados 
na Revista Portuguesa de Pneumologia, de preferência nos 
últimos 6 meses, ou relatando de forma muito objectiva os 
resultados de observação clínica ou investigação original, que 
não justifiquem um tratamento mais elaborado. O texto deve 
ser limitado a 400 palavras, excluindo referências e tabelas, 
e incluir no máximo uma tabela ou figura e até 5 referências. 
As cartas ao editor não devem apresentar resumos. 
Bibliografia — As referências bibliográficas devem ser 
numeradas por ordem consecutiva da sua primeira citação no 
texto. Devem ser identificadas no texto com números árabes. 
As referências devem conter, no caso das revistas, o nome do 
primeiro autor (apelido e nome), seguido dos restantes, do 
título do artigo, do nome da publicação e da sua identificação 
(ano, volume e páginas).
Pode ser encontrada nos “Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals” uma descrição 
pormenorizada do formato dos diferentes tipos de referências, 
de que se acrescenta um exemplo: 
Vega KJ, Pina I, Krevsky B. Heart transplantation is associated 
with an increase risk for pancreatobiliary disease. Ann Intern 
Med 1996;124:980-3. 
Quadros e figuras — Os quadros e figuras devem ser 
apresentados em páginas separadas, em condições de 
reprodução, de acordo com a ordem em que são discutidas 
no texto. Devem ser acompanhados da respectiva legenda de 
modo a serem compreendidas e interpretadas sem recurso ao 
texto manuscrito. Todos os gráficos deverão ser apresentados 
através de fotografia do respectivo original. Não devem 
ser enviados originais de fotografias, ilustrações ou outros 
materiais como películas de raio-X. As figuras, criadas em 
computador, ou convertidas em formato electrónico após 
digitalização, devem ser inseridas no ficheiro do manuscrito. 
Os custos da publicação das figuras a cores serão suportados 
pelos autores. Em caso de aceitação do manuscrito, serão 
solicitadas as figuras nos formatos mais adequados para a 
produção da revista. 
Anexos — Material muito extenso para a publicação com 
o manuscrito, designadamente tabelas muito extensas ou 
instrumentos de recolha de dados, poderá, nos casos em que 
for considerado, ser colocado apenas na página de Internet 
para consulta pelos interessados (Material suplementar). 
Considerações éticas e consentimento informado - Os autores 
devem assegurar que todas as investigações envolvendo 
seres humanos foram aprovadas por comissões de ética das 
instituições em que a investigação tenha sido desenvolvida, de 
acordo com a Declaração de Helsínquia da Associação Médica 
Mundial (www.wma.net). Na secção de métodos do manuscrito 
deve ser mencionada esta aprovação e a obtenção de 
consentimento informado, quando aplicável. Na submissão de 
casos clínicos deve constar especificamente o consentimento 
dos doentes em causa.
Conflitos de interesse — Os autores de qualquer manuscrito 
submetido devem revelar no momento da submissão a 
existência de conflitos de interesse ou declarar a sua 
inexistência. Essa informação será mantida confidencial 
durante a revisão do manuscrito pelos avaliadores externos e 
não influenciará a decisão editorial mas será publicada se o 
artigo for aceite. 
Modificações e revisões — No caso da aceitação do artigo 
ser condicionada a modificações, estas devem ser realizadas 
pelos autores no prazo de quinze dias (no caso de modificações 
«minor») ou 2 meses (no caso de modificações «major»). As 
provas tipográficas serão da responsabilidade da Redacção, se 
os autores não indicarem o contrário. Neste caso elas deverão 
ser feitas no prazo determinado pela Redacção, em função 
das necessidades editoriais da Revista. Os autores receberão 
as provas para publicação em formato PDF para correcção e 
deverão devolvê-las à redacção da revista num prazo de 48 
horas.
SUBMISSÃO DE MANUSCRITOS 
Os manuscritos submetidos à REVISTA PORTUGUESA DE 
PNEUMOLOGIA devem ser preparados de acordo com as 
recomendações acima indicadas e devem ser acompanhados 
de uma carta de apresentação («cover letter»). O conselho 
editorial, ao tomar conhecimento dos manuscritos, enviará 
uma informação acerca da orientação dada ao referido artigo. 
Sempre que sejam sugeridas alterações aos manuscritos 
enviados pelo conselho editorial, os autores deverão enviar a 
nova versão com a explicação das modificações efectuadas. 
A correspondência entre os autores e a revista deverá ser 
efectuada através da Plataforma da Elsevier em http://www.
ees.elsevier.com/rpp/
